With over 18,000 registered AML clinical trials worldwide and a 5 year relative survival rate around 30 percent in the United States, Acute Myeloid Leukemia is a disease where the gap between research activity and patient outcomes is stark. Yet newer trial endpoints such as CRi and MRD negativity, plus mutation guided care for targets like FLT3 and IDH1/2, are reshaping how outcomes are measured. These AML statistics connect survival, treatment fit, and genetics in ways that often surprise even seasoned readers.
Key Takeaways
- 5-year relative survival for AML in the United States is about 30% (SEER, all races)
- In unfit older AML patients, median overall survival historically ranges around 4–10 months depending on regimen (review estimates)
- Measurable residual disease (MRD) negativity is associated with improved survival in AML across multiple studies (MRD prognostic meta findings)
- NCCN recommends molecular testing for mutations including FLT3 and IDH1/2 in AML to guide targeted therapy selection
- Azacitidine is one of the commonly used hypomethylating agents for AML patients who are unfit for intensive chemotherapy
- Complete remission with incomplete hematologic recovery (CRi) and measurable residual disease (MRD) negativity are common endpoints in AML trials evaluating targeted therapies
- Venetoclax in combination with azacitidine has demonstrated improved overall survival vs azacitidine alone in AML patients ineligible for intensive chemotherapy (5-year follow-up reports)
- Azacitidine vs conventional care regimens showed improved overall survival in AML patients unfit for intensive chemotherapy (median OS reported in pivotal trial)
- Decitabine vs conventional care regimens improved survival in certain older unfit AML populations (median OS reported in randomized trial)
- NPM1-mutated AML is associated with cytogenetically normal disease frequently; NPM1 mutation prevalence reported around 30% of AML (review)
- WHO classification updates for AML categories rely on genetic and clinical features including defining mutations (framework described in WHO/ICC updates)
- In 2024, there were 18,000+ registered clinical trials for AML worldwide on ClinicalTrials.gov (aggregate count for AML condition tag)
- The global oncology therapeutics market is measured in the hundreds of billions USD annually (context for AML within oncology)
- The acute leukemia segment is included within broader hematology cancer drug markets measured in billions of dollars globally (hematology oncology market sizing)
- The global CAR-T therapy market is projected to exceed $10 billion; AML is a target indication in ongoing development (adjacent hematologic malignancies)
AML survival remains low but targeted testing and drugs like azacitidine plus venetoclax improve outcomes.
Related reading
01 · Category
Survival Outcomes3 stats
01
5-year relative survival for AML in the United States is about 30% (SEER, all races)https://seer.cancer.gov/statfacts/html/amyl.html
02
In unfit older AML patients, median overall survival historically ranges around 4–10 months depending on regimen (review estimates)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472641/
03
Measurable residual disease (MRD) negativity is associated with improved survival in AML across multiple studies (MRD prognostic meta findings)https://pubmed.ncbi.nlm.nih.gov/28012986/
Interpretation
Survival Outcomes Interpretation
For the Survival Outcomes outlook in AML, the overall 5-year relative survival in the United States is only about 30%, reflecting that many unfit older patients historically live roughly 4 to 10 months, yet the key prognostic bright spot is that achieving MRD negativity is linked with better survival across multiple studies.
02 · Category
Clinical Management3 stats
01
NCCN recommends molecular testing for mutations including FLT3 and IDH1/2 in AML to guide targeted therapy selectionhttps://www.nccn.org/guidelines/guidelines-detail?category=1&id=1449
02
Azacitidine is one of the commonly used hypomethylating agents for AML patients who are unfit for intensive chemotherapyhttps://www.ema.europa.eu/en/medicines/human/EPAR/vidaza
03
Complete remission with incomplete hematologic recovery (CRi) and measurable residual disease (MRD) negativity are common endpoints in AML trials evaluating targeted therapieshttps://www.nejm.org/doi/full/10.1056/NEJMoa1905782
Interpretation
Clinical Management Interpretation
In clinical management of AML, major guidelines and trial endpoints emphasize tailoring therapy to molecular findings such as FLT3 and IDH1/2 and using agents like azacitidine for patients unfit for intensive chemotherapy, with CRi plus MRD negativity emerging as a common success measure.
03 · Category
Therapies & Pipelines7 stats
01
Venetoclax in combination with azacitidine has demonstrated improved overall survival vs azacitidine alone in AML patients ineligible for intensive chemotherapy (5-year follow-up reports)https://www.nejm.org/doi/full/10.1056/NEJMoa2012887
02
Azacitidine vs conventional care regimens showed improved overall survival in AML patients unfit for intensive chemotherapy (median OS reported in pivotal trial)https://www.nejm.org/doi/full/10.1056/NEJMoa1114112
03
Decitabine vs conventional care regimens improved survival in certain older unfit AML populations (median OS reported in randomized trial)https://www.nejm.org/doi/full/10.1056/NEJMoa1006765
04
CPX-351 improved overall survival vs 7+3 in therapy-related AML and AML with myelodysplasia-related changes (pivotal trial median OS reported)https://www.nejm.org/doi/full/10.1056/NEJMoa1708924
05
Gilteritinib improved overall survival vs investigator’s choice chemotherapy in relapsed or refractory FLT3-mutated AML (ADMIRAL trial reported OS)https://www.nejm.org/doi/full/10.1056/NEJMoa2002622
06
Ivosidenib improved outcomes vs placebo in relapsed/refractory IDH1-mutated AML (AGILE trial reported OS metrics)https://www.nejm.org/doi/full/10.1056/NEJMoa1906981
07
Enasidenib improved survival vs placebo in relapsed/refractory IDH2-mutated AML (pivotal trial reported outcomes)https://www.nejm.org/doi/full/10.1056/NEJMoa1604057
Interpretation
Therapies & Pipelines Interpretation
For the Therapies and Pipelines angle, multiple AML pathway targeted and low intensity regimens are showing survival gains that persist in pivotal follow ups, including Venetoclax plus azacitidine improving overall survival versus azacitidine alone with 5 year follow up results while agents like CPX-351, gilteritinib, ivosidenib, and enasidenib also report overall survival improvements in their respective high risk settings.
04 · Category
Biomarkers1 stats
01
NPM1-mutated AML is associated with cytogenetically normal disease frequently; NPM1 mutation prevalence reported around 30% of AML (review)https://pubmed.ncbi.nlm.nih.gov/27960114/
Interpretation
Biomarkers Interpretation
From a biomarkers perspective, NPM1 mutations appear in roughly 30% of AML cases and are often linked to cytogenetically normal disease, suggesting a relatively common molecular marker with clear diagnostic and prognostic relevance.
More related reading
05 · Category
Industry Trends2 stats
01
WHO classification updates for AML categories rely on genetic and clinical features including defining mutations (framework described in WHO/ICC updates)https://www.hem.org/education/clinician-update/white-paper-on-who-classification-of-aml
02
In 2024, there were 18,000+ registered clinical trials for AML worldwide on ClinicalTrials.gov (aggregate count for AML condition tag)https://clinicaltrials.gov/search?cond=Acute%20Myeloid%20Leukemia&aggFilters=status:rec
Interpretation
Industry Trends Interpretation
With WHO and ICC AML category updates increasingly grounded in genetic and clinical feature frameworks, the scale of that precision is underscored by more than 18,000 registered AML clinical trials worldwide on ClinicalTrials.gov in 2024, signaling major industry momentum around mutation informed care.
06 · Category
Market Size4 stats
01
The global oncology therapeutics market is measured in the hundreds of billions USD annually (context for AML within oncology)https://www.imarcgroup.com/oncology-market
02
The acute leukemia segment is included within broader hematology cancer drug markets measured in billions of dollars globally (hematology oncology market sizing)https://www.alliedmarketresearch.com/hematology-oncology-drugs-market
03
The global CAR-T therapy market is projected to exceed $10 billion; AML is a target indication in ongoing development (adjacent hematologic malignancies)https://www.globenewswire.com/news-release/2024/03/05/2843914/0/en/CAR-T-Cell-Therapy-Market-Size-to-Reach-US-10-5-Billion-by-2031-IMARC-Group.html
04
Medicare data show that beneficiaries with leukemia generate higher spending compared with many other cancer types; leukemia spending is reported in national analyseshttps://www.healthaffairs.org/content/forefront/medicare-spending-by-cancer-type
Interpretation
Market Size Interpretation
The market size outlook for acute myeloid leukemia is supported by the fact that oncology therapeutics are measured in the hundreds of billions of dollars annually, with acute leukemia fitting within hematology drug markets worth billions globally, while next generation options like CAR T are projected to exceed $10 billion worldwide and leukemia consistently drives higher Medicare spending than many other cancer types.
07 · Category
Epidemiology3 stats
01
GLOBOCAN estimates leukemia (all types) accounts for a measurable share of global cancer incidence; AML is a major component (IARC fact sheet)https://gco.iarc.fr/today/data/factsheets/cancers/10-Leukemia-fact-sheet.pdf
02
IARC GLOBOCAN provides annual global incidence and mortality estimates for leukemia, which includes AMLhttps://gco.iarc.fr/today/fact-sheets-cancers
03
The National Cancer Institute lists AML as a cancer with risk increasing with age and median diagnosis age around 68 (NCI/SEER)https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, AML is a major part of the global leukemia burden tracked by IARC GLOBOCAN through annual incidence and mortality estimates, and in the United States its risk steadily rises with age with a median diagnosis around 68, underscoring how both population level incidence and aging shape who develops AML.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Alexander Schmidt. (2026, February 13). Acute Myeloid Leukemia Statistics. Gitnux. https://gitnux.org/acute-myeloid-leukemia-statistics
MLA
Alexander Schmidt. "Acute Myeloid Leukemia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/acute-myeloid-leukemia-statistics.
Chicago
Alexander Schmidt. 2026. "Acute Myeloid Leukemia Statistics." Gitnux. https://gitnux.org/acute-myeloid-leukemia-statistics.
Sources & references
23 datasets cited across this report
+9 additional datasets cited (not shown individually)